Overall, the pooled analysis showed that positive/high ERCC1 expression was significantly associated with shorter OS for SCLC patients receiving platinum-based chemotherapy (HR = 1.18, 95% CI = 1.02–1.37, I2 = 19.8%, P = 0.27 for heterogeneity; Table 2, Figure 3). This evidence concerns the gene ERCC1 and small cell lung carcinoma.